These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35881197)

  • 21. Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.
    Mao W; Cai Y; Chen D; Jiang G; Xu Y; Chen R; Wang F; Wang X; Zheng M; Zhao X; Mei J
    JCI Insight; 2022 Sep; 7(18):. PubMed ID: 35943796
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8
    Li A; Wang Y; Yu Z; Tan Z; He L; Fu S; Shi M; Du W; Luo L; Li Z; Liu J; Zhou Y; Fang W; Yang Y; Zhang L; Hong S
    J Thorac Oncol; 2023 Dec; 18(12):1714-1730. PubMed ID: 37495171
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
    Tsao MS; Le Teuff G; Shepherd FA; Landais C; Hainaut P; Filipits M; Pirker R; Le Chevalier T; Graziano S; Kratze R; Soria JC; Pignon JP; Seymour L; Brambilla E
    Ann Oncol; 2017 Apr; 28(4):882-889. PubMed ID: 28137741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity to Immune Checkpoint Blockade in Advanced Non-Small Cell Lung Cancer Patients with
    Metro G; Baglivo S; Bellezza G; Mandarano M; Gili A; Marchetti G; Toraldo M; Molica C; Reda MS; Tofanetti FR; Siggillino A; Prosperi E; Giglietti A; Di Girolamo B; Garaffa M; Marasciulo F; Minotti V; Gunnellini M; Guida A; Sassi M; Sidoni A; Roila F; Ludovini V
    Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33946594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
    Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
    Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent High PD-L1 Expression and CD8
    Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
    Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
    Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer.
    Negrao MV; Lam VK; Reuben A; Rubin ML; Landry LL; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Gibbons DL; Wistuba II; Papadimitrakopoulou V; Glisson BS; Blumenschein GR; Lee JJ; Heymach JV; Zhang J
    J Thorac Oncol; 2019 Jun; 14(6):1021-1031. PubMed ID: 30780001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
    Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
    Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor mutational load, CD8
    Hurkmans DP; Kuipers ME; Smit J; van Marion R; Mathijssen RHJ; Postmus PE; Hiemstra PS; Aerts JGJV; von der Thüsen JH; van der Burg SH
    Cancer Immunol Immunother; 2020 May; 69(5):771-777. PubMed ID: 32047958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
    Mamesaya N; Muramatsu K; Yabe M; Kodama H; Nishioka N; Miyawaki T; Miyawaki E; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Naito T; Murakami H; Harada H; Sugino T; Shimizu T; Gon Y; Takahashi T
    Int J Clin Oncol; 2021 Apr; 26(4):659-669. PubMed ID: 33415571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.
    Kulshrestha R; Saxena H; Kumar R; Spalgais S; Mrigpuri P; Goel N; Menon B; Rani M; Mahor P; Bhutani I
    Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36723380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.
    Della Corte CM; Ciaramella V; Ramkumar K; Vicidomini G; Fiorelli A; Nardone V; Cappabianca S; Cozzolino I; Zito Marino F; Di Guida G; Wang Q; Cardnell R; Gay CM; Ciardiello D; Martinelli E; Troiani T; Martini G; Napolitano S; Wang J; Byers LA; Ciardiello F; Morgillo F
    J Transl Med; 2022 Nov; 20(1):541. PubMed ID: 36419183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
    Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
    Thompson JC; Davis C; Deshpande C; Hwang WT; Jeffries S; Huang A; Mitchell TC; Langer CJ; Albelda SM
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33028693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
    BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
    Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
    J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.